> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Rx-to-OTC Switch for Antihistamine
- URL: https://www.fdaweb.com/fda-oks-rx-to-otc-switch-for-antihistamine/
- Published: 2021-06-18T12:00:00.000Z
- Updated: 2026-09-14T17:04:00.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149573

FDA has approved Bayer Healthcare’s Astepro (azelastine hydrochloride nasal spray, 0.15%), a nasal antihistamine for nonprescription use under an Rx-to-OTC switch. Astepro is indicated for treating seasonal and perennial allergic rhinitis for adults and children six years of age and older. The approval is a first-in-class switch for a nasal antihistamine and is considered a partial switch because the 0.1% strength, which includes the perennial allergy indication for children six months to six years old and seasonal allergy indication for children two to six years old, will remain prescription only.